Pro MedicusASX:PME +3.50%98 EBITDA Margin % is 75.58% as of Dec. 2025, which is 8% above its 10-year median of 69.71. GuruFocus rates ASX:PME with a GF Score™ of 98/100 and a GF Value™ of A$244.83 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 668 Healthcare Providers & Services companies, Pro Medicus ranks better than 98.65% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Pro Medicus's EBITDA for the
six
months ended in Dec. 2025 was A$94.3 Mil. Pro Medicus's Revenue for the
six
months ended in Dec. 2025 was A$124.7 Mil. Therefore, Pro Medicus's EBITDA margin for the quarter that ended in Dec. 2025 was 75.58%.
Pro Medicus (ASX:PME) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Pro Medicus EBITDA Margin % Related Terms
Pro Medicus EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Pro Medicus's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:PME vs VEEV, BTSG, TEM: EBITDA Margin % Comparison
For the Health Information Services subindustry, Pro Medicus's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pro Medicus EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pro Medicus's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Pro Medicus's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pro Medicus (ASX:PME) has a EBITDA Margin % of 75.58% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pro Medicus and its competitors. This is near median its historical median of 69.71. Over the past decade, Pro Medicus' EBITDA Margin % has ranged from 48.50 to 77.43. According to the industry distribution chart, Pro Medicus ranks #9 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 1.3%.
Is Pro Medicus' EBITDA Margin % too high?
Pro Medicus' current EBITDA Margin % of 75.58% is near median its 10-year median of 69.71. Over the past 10 years, this metric has ranged from a low of 48.50 to a high of 77.43. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Pro Medicus' value of 75.58% is 640.3% above this industry median. Based on the distribution chart, Pro Medicus ranks #9 out of 668 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Pro Medicus has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pro Medicus' EBITDA Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Pro Medicus ranks #9 out of 668 companies for EBITDA Margin %. This places Pro Medicus in the top 1% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.21. Pro Medicus' value of 75.58% is 640.3% above this benchmark. Historically, Pro Medicus' own EBITDA Margin % has ranged from 48.50 to 77.43 over the past decade. While the company's 10-year median is 69.71 vs. the industry median of 10.21, Pro Medicus has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pro Medicus's current EBITDA Margin % of 75.58% is 640.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pro Medicus and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pro Medicus's current EBITDA Margin % is 75.58%, which is near median its own 10-year median of 69.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pro Medicus stock overvalued right now?
Based on GuruFocus' analysis, Pro Medicus (ASX:PME) is currently considered Modestly Undervalued. The stock's GF Value™ is A$244.83, compared to a current price of A$178.99 — trading 26.9% below its estimated fair value. The current EBITDA Margin % is 75.58%, which is near median its 10-year median of 69.71 and 640.3% above the Healthcare Providers & Services industry median of 10.21. Pro Medicus' overall GF Score™ is 98/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Pro Medicus (ASX:PME), the current EBITDA Margin % is 75.58% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pro Medicus (ASX:PME) Overvalued in 2026?
Based on GuruFocus' analysis, Pro Medicus stock appears to be undervalued.
The current stock price of A$178.99 is trading 26.9% below its estimated GF Value™ of A$244.83.
GuruFocus considers Pro Medicus to be Modestly Undervalued.
Key valuation signals for ASX:PME:
EBITDA Margin %: 75.58% (near median its 10-year median of 69.71)
GF Value™: A$244.83 vs. price of A$178.99 (26.9% below fair value)
Industry Position: 640.3% above the Healthcare Providers & Services median (#9 of 668)
No single metric tells the full story. See the ASX:PME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are US private academic hospitals. In fiscal 2025, Pro Medicus earned 90% of revenue in North America, 8% from Australia, and the remaining 2% in Europe.
98GF Score
Get the complete analysis for ASX:PME
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PME has been successfully added to your 
